Insulin resistance in type 1 diabetes is a key modulator of platelet hyperreactivity.

AIMS/HYPOTHESIS: Individuals with type 1 diabetes are at increased cardiovascular risk, particularly in the presence of insulin resistance. A prothrombotic environment is believed to contribute to this risk but thrombotic pathways in type 1 diabetes are only partially understood and the role of platelets is incompletely studied. We hypothesised that platelets from individuals with type 1 diabetes exhibit platelet hyperactivity due to both increased propensity for activation and diminished sensitivity to inhibition, with an amplified maladaptive phenotype in those with insulin resistance.

METHODS

Blood samples were obtained from individuals with type 1 diabetes enrolled on the 'Double diabEtes and adVErse cLinical Outcome: identification of mechanistic Pathways' (DEVELOP) study with insulin resistance assessed as estimated glucose disposal rate (eGDR), whereby eGDR >8 or <6 mg kg min indicates normal insulin sensitivity or advanced insulin resistance, respectively. Platelet function was analysed using whole blood multiparameter flow cytometry to simultaneously measure three distinct markers of activation, including integrin αβ (PAC-1 binding), P-selectin (CD62P) and phosphatidylserine (PS) (Annexin V). Both activation and inhibition responses of the platelets were investigated, which were subjected to the machine learning tool Full Annotation Shape-constrained Trees (FAUST) to characterise platelet subpopulations.

RESULTS

A total of 32 individuals with type 1 diabetes were studied (median age [range] of 24 [18-34] years, 59% male, diabetes duration [mean ± SD] of 14.0 ± 6.3 years and HbA of 65.3 ± 14.0 mmol/mol [8.1%]). An increased basal expression, measured as mean fluorescence intensity, of all three platelet activation markers was detected in the type 1 diabetes group compared with healthy control participants (CD62P expression 521 ± 246 vs 335 ± 67; p<0.001, PAC-1 370 ± 165 vs 231 ± 88; p=0.011 and PS 869 ± 762 vs 294 ± 109; p=0.001). Following platelet stimulation, an enhanced activation of these markers was found in the type 1 diabetes group. Within the type 1 diabetes group, those with advanced insulin resistance (eGDR<6 mg kg min) showed increased platelet activation compared with individuals with normal insulin sensitivity (eGDR>8 mg kg min) with single agonist stimulation CD62P expression (29,167 ± 2177 vs 22,829 ± 2535, p<0.001 and PAC-1 19,339 ± 11,749 and 5187 ± 2872, p=0.02). Moreover, individuals with type 1 diabetes showed reduced sensitivity to platelet inhibition by prostacyclin (PGI) compared with control participants. Stratification of individuals with type 1 diabetes by insulin resistance demonstrated that in the presence of PGI, suppression of stimulated CD62P was 17 ± 11% and 33 ± 12% (p=0.02) for advanced insulin resistance and normal insulin sensitivity groups, respectively, with even larger differences demonstrated for PAC-1 (48 ± 17% and 75 ± 7%; p=0.006) and PS exposure (33 ± 12% and 84 ± 10%; p=0.001). Furthermore, FAUST analysis showed that, under basal conditions, there was a different distribution of the eight platelet subpopulations comparing advanced insulin resistance and normal insulin sensitivity groups, with differences also detected following PGI inhibition.

CONCLUSIONS/INTERPRETATION: Our novel characterisation of platelets in type 1 diabetes shows a maladaptive phenotype with increased basal activity together with hyperactivation following stimulation and diminished responses to inhibition. Insulin resistance appears to further drive this adverse thrombotic phenotype, suggesting an enhanced platelet-driven cardiovascular risk in those with type 1 diabetes and reduced insulin sensitivity.